BREAKOUT STOCK ALERT
GLMD - Galmed Pharmaceuticals Ltd. - Ordinary Shares
Initial Alert Price: $3.67
Potential Price: $4.32
Potential Gains: 17.71
Stop Loss Limit: $
GLMD is working to retest the $4.32 Levels of Resistance and if it's able to breakthrough and we find support at those price levels, we can expect this to move forward in retesting the $5.15 Price Ranges. The company is currently conducting Phase 3 Trials for their drug Aramchol, which focuses on Non-Alcoholic Steatohepatitis and Liver Fibrosis. The company also has a 2nd Drug in Phase 3 Trials, Amilo-5MER for Chronic Inflammatory Disorders. The company will be hosting a symposium to give an update on the pipeline for the continued development, progress of clinical trials, and manufacturing/distribution moving into the future. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
GLMD - Galmed Pharmaceuticals Ltd. - Ordinary SharesInitial Alert Price: $3.67
Potential Price: $4.32
Potential Gains: 17.71
Stop Loss Limit: $
GLMD is working to retest the $4.32 Levels of Resistance and if it's able to breakthrough and we find support at those price levels, we can expect this to move forward in retesting the $5.15 Price Ranges. The company is currently conducting Phase 3 Trials for their drug Aramchol, which focuses on Non-Alcoholic Steatohepatitis and Liver Fibrosis. The company also has a 2nd Drug in Phase 3 Trials, Amilo-5MER for Chronic Inflammatory Disorders. The company will be hosting a symposium to give an update on the pipeline for the continued development, progress of clinical trials, and manufacturing/distribution moving into the future. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.